Another treatment option for eczema sufferers approved by the FDA
The US Food and Drug Administration (FDA) has approved Eucrisa (Crisaborole), manufactured by Pfizer Inc., for the treatment of mild to moderate atopic dermatitis, more commonly known as eczema, in patients aged 2 years and older. Eczema is a chronic inflammatory skin disease, which is a general term for the several types of inflammation of the skin, characterized by red, scaly and crusted bumps, which are extremely itchy; Atopic Dermatitis is the most common form of eczema. Atopic dermatitis is caused by a combination of genetic, immune and environmental factors, and typical onset is in childhood and can last throughout adulthood, impacting nearly 18 million children and adults in the United States.
Amy Egan, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and research, was quoted as saying “Today’s approval provides another treatment option for patients dealing with mild to moderate atopic dermatitis.”
Eucrisa is a phosphodiesterase 4 inhibitor that is applied topically twice daily; its specific mechanism of action in atopic dermatitis is unknown.
The safety and efficacy of Eucrisa were established in two placebo-controlled trials with a total of 1522 participants ranging from 2 years of age to 79 years of age, all suffering with mild to moderate atopic dermatitis. Overall, participants receiving Eucrisa achieved greater response with clear or almost clear skin after 28 days of treatment.
Side effects to Eucrisa may include hypersensitivity reactions, usually as a result of Eucrisa’s active ingredient crisaborole. The most common side effect is application site pain and sensitivity, including burning or stinging.
Eucrisa is manufactured by Palo Alto, California based Anacor Pharmaceuticals, Inc. recently purchased by Pfizer Inc.
As with any medication, it is important to always consult your doctor or physician as to whether Eucrisa is a suitable treatment option for your Atopic Dermatitis.